Tri:ChAd:TB
Candidate Overview
Tri:ChAd:TB is built on the chimpanzee adenovirus serotype 68 vector, expressing Ag85A, TB10.4, and RpfB. These antigens spanning distinct M.tb life-cycle stages. Ag85A wanes after acute infection, whereas TB10.4 remains highly expressed. RpfB is upregulated during dormancy and resuscitation. This vaccine is formulated for respiratory mucosal delivery.
Sponsor / Lead Developer: McMaster University
Primary Indication: Prevention of Mtb infection or sustained infection
Other Indication(s): Immunotherapy/Improving TB Cure Rates, Immunotherapy/Shortening TB treatment, Prevention of TB disease, and Prevention of TB recurrence
Target Population(s): Adolescents and Adults
Target Route of Administration: Aerosol
Immune tissue localization: Lung
Immunological responses: T-cell
Preclinical Animal Models: Mouse
Intended to elicit trained immunity: Yes
Additional Immunologic Response Information
HYPOTHESIZED | DEMONSTRATED |
|
| Immune Response | T-cell | |
| T-cell phenotype | CD4 CD8 |
|
| T-cell functional profile | IL-17 Cytolytic Capacity Mycobacterial growth inhibition | IFN-γ TNF-α |
| Preferential immune tissue localization | Lung | |
| Trained immunity | Yes | |